MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells

Xiaojun Ge1, Limei Zheng2, Min Huang3

  • 1Department of Medical Oncology and Laboratory of Signal Transduction and Molecular Targeted Therapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

Insights

Researchers developed gefitinib-resistant lung cancer cells to study acquired resistance mechanisms. They found that decreased miR-7 expression is linked to this resistance, suggesting miR-7 could reverse drug resistance in lung adenocarcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Acquired resistance to gefitinib is a significant challenge in treating lung adenocarcinoma.
  • Understanding the molecular mechanisms underlying this resistance is crucial for developing effective therapeutic strategies.

Purpose of the Study:

  • To establish and characterize gefitinib-resistant human lung cancer cells (A549).
  • To elucidate the potential mechanisms of acquired gefitinib resistance, focusing on microRNA (miRNA) expression profiles.
  • To investigate the role of specific miRNAs, particularly miR-7, in gefitinib resistance.

Main Methods:

  • Establishment of gefitinib-resistant A549 sub-clones through prolonged drug exposure.
  • Quantification of drug sensitivity using half maximal inhibitory concentration (IC50) values via real-time cytotoxicity assays.
  • MicroRNA expression profiling using microfluidic biochip microarrays.
  • Bioinformatic analysis to predict target genes of differentially expressed miRNAs.
  • Validation of miRNA expression using quantitative polymerase chain reaction (qPCR).
  • Functional analysis using miRNA mimics and western blotting to assess protein expression.

Main Results:

  • Gefitinib-resistant cells exhibited a 3-fold increase in IC50 values and distinct morphological changes compared to parent cells.
  • Microarray analysis revealed 25 upregulated and 18 downregulated miRNAs in resistant cells.
  • Quantitative polymerase chain reaction confirmed significant downregulation of miR-7 in gefitinib-resistant cells.
  • Functional studies indicated that miR-7 may enhance cancer cell sensitivity to gefitinib.

Conclusions:

  • MicroRNAs are implicated in the acquired gefitinib resistance of lung adenocarcinoma.
  • Downregulation of miR-7 is associated with gefitinib resistance.
  • Restoring miR-7 levels may represent a potential therapeutic strategy to overcome gefitinib resistance in lung cancer patients.